This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Zacks News
HOOKIPA Pharma Inc. (HOOK) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
HOOKIPA Pharma Inc. (HOOK) delivered earnings and revenue surprises of -12.50% and 15.31%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Shattuck Labs, Inc. (STTK) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Shattuck Labs, Inc. (STTK) delivered earnings and revenue surprises of 19.67% and 83.24%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Akoya Biosciences (AKYA) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Akoya (AKYA) delivered earnings and revenue surprises of -6.52% and 5.11%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Arvinas, Inc. (ARVN) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Arvinas, Inc. (ARVN) delivered earnings and revenue surprises of -5.48% and 5.88%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Blueprint Medicines (BPMC) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Blueprint Medicines (BPMC) delivered earnings and revenue surprises of 19.17% and 48.18%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Biogen (BIIB) Beats on Q1 Earnings, Ends Some Research Programs
by Zacks Equity Research
Biogen (BIIB) beats first-quarter estimates for earnings and sales. It maintains its 2023 guidance. Stock drops in pre-market trading.
Assertio (ASRT) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
On Assertio Therapeutics' (ASRT) Q1 earnings call, investors will likely focus on the sales performance of its rheumatology, pain and inflammation medicines.
Best Momentum Stocks to Buy for April 12th
by Zacks Equity Research
CELU, PPG and LSCC made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on April 12, 2023.
New Strong Buy Stocks for April 12th
by Zacks Equity Research
CELU, MGI, LRMR, EQRX and SRZN have been added to the Zacks Rank #1 (Strong Buy) List on April 12, 2023.
Immuneering Corporation (IMRX) Surges 18.5%: Is This an Indication of Further Gains?
by Zacks Equity Research
Immuneering Corporation (IMRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Celularity, Inc. (CELU) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Celularity, Inc. (CELU) closed at $0.59, marking a -0.69% move from the previous day.
Celularity, Inc. (CELU) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Celularity, Inc. (CELU) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Celularity (CELU) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Devoid of marketed drugs, investors will focus on updates on Celularity's (CELU) pipeline candidates when it reports its fourth-quarter earnings.
Investors Heavily Search Celularity, Inc. (CELU): Here is What You Need to Know
by Zacks Equity Research
Celularity, Inc. (CELU) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Celularity, Inc. (CELU) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Celularity, Inc. (CELU) closed at $0.74, marking a +1.36% move from the previous day.
Celularity, Inc. (CELU) Stock Moves -0.11%: What You Should Know
by Zacks Equity Research
Celularity, Inc. (CELU) closed at $0.64 in the latest trading session, marking a -0.11% move from the prior day.
Here is What to Know Beyond Why Celularity, Inc. (CELU) is a Trending Stock
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Celularity, Inc. (CELU). This makes it worthwhile to examine what the stock has in store.
Celularity, Inc. (CELU) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Celularity, Inc. (CELU) closed at $0.74 in the latest trading session, marking a +1.73% move from the prior day.
Celularity, Inc. (CELU) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Celularity, Inc. (CELU) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Celularity, Inc. (CELU) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Celularity, Inc. (CELU) closed at $0.95, marking a -1.7% move from the previous day.
Celularity, Inc. (CELU) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Zacks.com users have recently been watching Celularity, Inc. (CELU) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Mirati (MRTX) KRAS Candidate MRTX1133 to Enter Clinical Stage
by Zacks Equity Research
Mirati Therapeutics (MRTX) announces IND clearance for oral KRASG12D selective inhibitor, MRTX1133, by the FDA. It is set to initiate phase I/II study in early 2023.
Horizon (HZNP) Dazodalibep Meets Goal in Sjogren's Syndrome Study
by Zacks Equity Research
Horizon Therapeutics (HZNP) announces that a phase II Sjogren's syndrome study of its candidate, dazodalibep, meets the primary endpoint for the second population.
Angion (ANGN) Down on Merger Agreement With Private Biotech
by Zacks Equity Research
Angion (ANGN) inks a definitive merger agreement with privately-held Elicio Therapeutics. The combined company's lead pipeline candidate will be ELI-002, a therapeutic cancer vaccine targeting mKRAS-driven tumors.
Roche (RHHBY) Gets EU Approval for Xofluza in New Patient Base
by Zacks Equity Research
The European Commission approves Roche's (RHHBY) Xofluza for treating uncomplicated influenza and post-exposure prophylaxis of influenza in children aged one year and above.